$ICUI

ICU Medical (ICUI) VP, General Counsel Virginia Sanzone Sells 4,

ICU Medical Inc's (ICUI) VP and General Counsel Virginia Sanzone sold 4,856 shares at $168.69 each, totaling $819,000. She has sold 8,233 shares in the past year with no purchases. The company's stock has a P/E ratio of 140.92, higher than industry and historical averages. GuruFocus values the stock at $120.76, suggesting it is significantly overvalued.

Original reporting
Published Sep 4, 2026, 7:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 2:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ICUI
Bearish
medium confidence
Mentioned
$ICUI
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ICUIBearishLow
01

Why it matters

The disclosed insider sale adds a negative data point but is unlikely to drive major price movement.

02

Market read

Routine insider transaction; modest relevance for traders watching ICUI.

03

What to watch

High valuation multiples suggest the stock may be overvalued regardless of insider actions.

Relevance 4/10Novelty 3/10Timing: September 3, 2026 (same-day filing)

Background

ICU Medical develops infusion therapy and critical care devices; its stock trades around $168 with a high P/E.

Company-level read

Ticker impact

$ICUIBearishMedium confidence
Context

VP and General Counsel Virginia Sanzone sold 4,856 shares at $168.69, a $819k insider sale disclosed via SEC Form 4.

Expected impact

Potential short-term pressure on ICUI stock, likely limited to a few percent.

Evidence & confidence

Insider sales often weigh on sentiment, yet the sale size is small for a $4.2B market cap and may be personal.

Market effects

May raise caution among medical device investors monitoring insider activity.

Limited to US healthcare sector sentiment.

Minimal global impact.

Counterpoint

The sale could be unrelated to outlook; insiders often sell for tax or liquidity reasons.

Key entities

  • Virginia Sanzone

    Vice President and General Counsel of ICU Medical.

Related articles

$ICUIMed

ICU Medical rating upgraded by S&P on stronger credit metrics

S&P Global Ratings upgraded ICU Medical Inc. to 'BB' from 'BB-', citing improved credit metrics and strong operating performance. The company's adjusted leverage decreased to 3.1x in Q2 2026, with free operating cash flow exceeding expectations. ICU Medical used proceeds from asset sales and cash flow to reduce debt. S&P projects mid-single-digit revenue growth and margin improvement through 2027, with a stable outlook based on expected debt and cash flow metrics.

$ICUIMedAI 8/10

ICU Medical (ICUI) Q2 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.

$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ:ICUI) shares rose 10.2% after the company reported Q2 results that beat Wall Street and lifted full-year guidance. Adjusted EPS was $2.37 vs $1.91 expected, revenue was $551.7 million vs forecasts, and free cash flow improved to $61.64 million. Full-year adjusted EPS guidance was raised to $8.80 (midpoint).

$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ: ICUI) shares rose 10.2% after the company reported Q2 adjusted EPS of $2.37, above the $1.91 consensus, and revenue of $551.7 million, above forecasts. Free cash flow improved to $61.64 million from -$8.49 million a year earlier. ICU Medical raised full-year adjusted earnings guidance to $8.80 per share (midpoint).

$ICUIMedAI 8/10

ICU Medical (NASDAQ:ICUI) Reports Strong Q2 CY2026

ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results. Revenue rose 1.5% year over year to $551.7 million, beating Wall Street’s revenue estimate by 3.5%. Non-GAAP adjusted EPS was $2.37, up from $2.10 and 23.8% above consensus. The stock rose 1.4% to $168.02 after the release.